BRD4-BD1/2-IN-2 is a potent BRD4 BD2 inhibitor with IC50s of <0.5 nM and <300 nM for BRD4 BD2 and BRD4 BD1, respectively (WO2021233371A1, compound 2).

DCN1-UBC12-IN-3 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.25 nM. Anticardiac fibrotic effect.

RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321).

NCGC00138783 selectively blocks the CD47/SIRPα interaction with an IC50 value of 40 μM for the cell surface binding. NCGC00138783 does not disrupt its binding to other receptors.

Gymconopin C shows an antiallergic effect on ear passive cutaneous anaphylaxis reactions in mice.

Morelloflavone has antioxidative, antiviral, and anti-inflammatory properties.

Tetracosactide acetate is a synthetic peptide stimulating the release of corticosteroids such as cortisol from the adrenal gland. Tetracosactide acetate is currently used for the research of ulcerative colitis and Crohn's disease, juvenile/adult rheumatoid arthritis and osteoarthrosis.

Aluminum Glycinate, an organo-metallic compound, is an antacid. Aluminum Glycinate can be used for the research of indigestion, acid reflux and ulcers.

ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.

Digoxigenin monodigitoxoside is a Na+/K+ ATPase inhibitor and cardiac glycoside metabolite of digoxin.

ent-Heronamide C has antifungal activity and is designed as probe for the mode-of-action analysis of heronamide C.

16,17-Dihydroheronamide C has antifungal activity and is designed as probe for the mode-of-action analysis of heronamide C.

(S)-(-)-MRJF22 is haloperidol metabolite II valproate ester. (S)-(-)-MRJF22 exhibits the high antimigratory effects in endothelial and tumor cells. (S)-(-)-MRJF22 is a potential multifunctional agent against uveal melanoma.

Setosusin ((+)-Setosusin) is a fungal meroditerpenoid featuring a unique spiro-fused 3(2H)-furanone moiety.

Cyanosafracin B is a starting material for synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650.

EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer.

KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).

KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).

Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).

Lubabegron is a potent modulator of β-adrenergic receptor (β -AR). Lubabegron demonstrates antagonistic behavior at the β1 and β 2 receptor subtypes and agonistic behavior at the β 3 receptor subtype in cattle. Lubabegron reduces NH3 gas emissions from an animal or its waste.

RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18).

ER-50891 is a potent antagonist of retinoic acid receptor α(RARα). ER-50891 significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis.

Phytochelatin 3 (PC 3) TFA is the small metal chelating peptide that can be used for chelating heavy metals.

Aszonapyrone A is a metabolite produced by Aspergillus zonatus.

Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC50 value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines.

Calpain-2-IN-1 is a calpain-2 selective inhibitor that enhances learning & memory by prolonging ERK activation.

Derquantel is a potent anthelmintic. Derquantel causes flaccid paralysis and expulsion of nematodes.

Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is LTD4 receptor antagonist.

Anticancer agent 28 showed good antitumor activity in H22 allogeneic mice in vivo. Its potency in K562 cells was 50 times that of oridonin, and its < b > IC < sub > 50 < / sub > < / b > value was 0.09 μ M。

Anticancer agent 26 deserves further development as a promising candidate for the treatment of cancer.